Announcement on the Company Passing ANVISA GMP Certification
Filed with SSE · · 2 pages · Chinese
Gan & Lee Pharmaceuticals Co., Ltd. on 6ix
Earlier from Gan & Lee Pharmaceuticals
- Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
- Announcement on Obtaining the Clinical Trial Approval Notification for the New Indication of Bofang Glutide (Development Code: GZR18) Injection
- Announcement on Appointment of Senior Management Members
- Announcement on Positive Opinion from the European Medicines Agency's CHMP on the Marketing Authorization Application for Insulin Lispro Injection (Bysumlog®) and Insulin Aspart Injection (Dazparda®)
- Announcement on Change of Sponsor Representative
Later from Gan & Lee Pharmaceuticals
- Announcement on Completion of Administration of the First Subject in Phase I Clinical Trial of GLR2037 Tablets
- Announcement on Obtaining Drug Registration Approval by Wholly-owned Subsidiary
- Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
- Announcement on Completion of Administration of the First Subject in Phase III Clinical Trial of GZR33 Injection
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial
Follow Gan & Lee Pharmaceuticals into a list and get an email when it puts out news.
Follow Gan & Lee Pharmaceuticals